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Purpose: To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/
dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically 
suspected acute viral conjunctivitis.
Patients and methods: This was a randomized, double-masked, parallel-group, vehicle-
controlled study. Adults with a clinical diagnosis of suspected acute viral conjunctivitis were 
randomized 1:1 to PVP-I/DEX ophthalmic suspension or vehicle bilaterally four times daily 
for 5 days (Days 1–5). Evaluation was on Days 1, 3 (+1-day window), and 6 (+1). Patients with 
signs of acute viral conjunctivitis at the Day 6 visit received open-label PVP-I/DEX for five 
additional days and were evaluated on Day 11–14. The primary efficacy endpoint was clinical 
resolution of acute viral conjunctivitis in the study eye at the Day 6 visit.
Results: Overall, 132 patients were randomized and received treatment (PVP-I/DEX, n=66; 
vehicle, n=66); 38 patients continued into the open-label portion of the study. Not enough 
patients with confirmed adenoviral conjunctivitis (n=32/132) were enrolled to assess the primary 
endpoint, although there were some efficacy trends in the PVP-I/DEX group for global clinical 
score (sum of watery conjunctival discharge and bulbar conjunctival redness). There were no 
serious treatment-emergent adverse events (TEAEs) and no patients discontinued due to a TEAE. 
In the masked phase, 56.1% of patients receiving PVP-I/DEX experienced at least one TEAE 
vs 43.9% in the vehicle group; 78.9% of patients in the open-label phase experienced at least 
one TEAE. Most TEAEs were mild in severity.
Conclusion: PVP-I/DEX ophthalmic suspension administered for #14 days had a favorable 
safety profile and was generally well tolerated.
Keywords: adenoviral conjunctivitis, dexamethasone, povidone-iodine, randomized 
controlled trial
Introduction
Infectious conjunctivitis is a common eye condition mainly caused by viruses and 
bacteria.1 Adenovirus is a frequent cause of infectious conjunctivitis, with reported 
rates of adenoviral conjunctivitis varying widely from 40% to 75% of all cases of 
infectious conjunctivitis.2–4 Adenoviral conjunctivitis is a public health concern due to 
its highly contagious nature.5 It is also associated with significant patient discomfort, 
lost productivity, and in rare cases can lead to complications such as subepithelial 
corneal infiltrates and permanent compromise of vision.6,7
Currently, there are no approved treatments for adenoviral conjunctivitis, with 
therapeutic options being limited to supportive therapies and palliative measures.7 
A novel ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 
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(DEX) 0.1% is currently under clinical investigation. PVP-I 
is an antiseptic with bactericidal, virucidal, and fungicidal 
properties.8 DEX is a corticosteroid routinely used as a 
topical ophthalmic suspension for the treatment of ocular 
inflammation.9 Both components are approved for use in 
other indications and have been shown to be safe and effica-
cious for use on the ocular surface in humans.10–13
Different ophthalmic formulations of PVP-I in combi-
nation with DEX have been investigated for the treatment 
of conjunctivitis in early-stage studies. In an in vivo study 
conducted in rabbits, PVP-I 0.4%/DEX 0.1% significantly 
improved clinical scores and viral titers vs control treat-
ments.14 In a randomized controlled trial of 122 patients with 
presumed viral conjunctivitis, treatment with ophthalmic 
PVP-I 0.4%/DEX 0.1% four times daily (QID) significantly 
reduced the duration of conjunctivitis vs patients treated 
with artificial tears.15 Similar results were obtained in a 
randomized controlled trial of 74 patients with adenoviral 
keratoconjunctivitis confirmed with polymerase chain reac-
tion (PCR). In that study, significantly faster improvement 
of clinical signs and adenoviral eradication (in 5–7 days) vs 
the control groups were observed in patients treated with 
PVP-I 1.0%/DEX 0.1%.16 In a recent Phase II randomized 
controlled study of 176 patients with acute adenoviral con-
junctivitis, ophthalmic administration of PVP-I 0.6%/DEX 
0.1% for 5 days demonstrated statistical superiority to vehicle 
for clinical resolution, adenoviral eradication, global clinical 
score, and expanded clinical cure.17
This report presents the results of a Phase II randomized 
controlled study conducted in Brazil to evaluate the clinical 
safety and efficacy of PVP-I 0.6%/DEX 0.1% ophthalmic 
suspension compared with vehicle in the treatment of patients 
with clinical suspicion of acute viral conjunctivitis.
Materials and methods
study design
This was a randomized, double-masked, parallel-group, 
vehicle-controlled study that was planned across two medical 
centers, although all patients were enrolled at a single site in 
Brazil. Patients were randomized 1:1 to receive either PVP-I 
0.6%/DEX 0.1% ophthalmic suspension or vehicle, instilled 
as a single drop in both eyes QID for 5 days. The study con-
sisted of four visits over 11–14 days. Visit 1 occurred on Day 1, 
Visit 2 on Day 3+1-day window, Visit 3 on Day 6+1-day 
window, and Visit 4 on Days 11–14 (ie, visit 3+5–7 days; 
Figure 1). Visit 4 was only required for patients with signs 
of acute viral conjunctivitis in the study eye at Visit 3, with 
those patients receiving open-label PVP-I 0.6%/DEX 0.1% 
for an additional 5 days (Figure 1). All study treatments were 
supplied as sterile preserved suspensions or solutions and 
were colored, labeled and packaged identically. Noncompli-
ance was recorded as a protocol deviation if .20% of doses 
during a given dosing period were missed.
Patients
Eligible patients were aged $18 years and had a best 
spectacle-corrected visual acuity (BSCVA) of 0.60 logarithm 
of the minimum angle of resolution (logMAR) or better in 
each eye, reported signs of viral conjunctivitis for #5 days 
before the study in at least one eye, clinical diagnosis of sus-
pected acute adenoviral conjunctivitis in at least one eye, and 
the presence of both watery conjunctival discharge and bulbar 
conjunctival redness score of $1 in the same eye (0–3 scale; 
0= absent/normal, 1= mild, 2= moderate, and 3= severe).
Exclusion criteria included the following: pregnancy 
or nursing a child; known sensitivity to any components 
of the investigational treatments; clinical signs, presence, 
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Figure 1 study design.
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or a history of herpes simplex keratitis; presence of ocular 
inflammation (eg, uveitis or iritis) or an ocular infection 
other than acute viral conjunctivitis; steroid responders 
with increased intraocular pressure or those with a history 
of glaucoma or elevated intraocular pressure .21 mmHg. 
In addition, patients with a history of recurrent corneal ero-
sion syndrome or with active ulcerative keratitis, clinically 
significant optic nerve defects visible upon non-dilated 
fundus examination at baseline, uncontrolled systemic 
disease, autoimmune disease, or debilitating disease were 
excluded. The use of investigational devices, contact lenses, 
and the following treatments were not allowed in the study: 
corticosteroids (not including stable use of inhaled or nasal 
corticosteroids and topical dermal steroids, except around 
the eyes), topical ocular or systemic antivirals, or any other 
topical ophthalmic solutions including tear substitutes 
and diagnostics.
Efficacy assessments
The primary efficacy endpoint was clinical resolution of acute 
viral conjunctivitis in the study eye at the Day 6 visit. Clinical 
resolution was defined as the absence (score =0) of both bul-
bar conjunctival redness and watery conjunctival discharge. 
Additional efficacy measurements included individual 
measurement of watery conjunctival discharge and bulbar 
conjunctival redness in the study eye, expanded clinical cure 
(a score of 0 or 1 for both bulbar conjunctival redness and 
watery conjunctival discharge, with at least one sign having 
a score of 0), and global clinical score (sum of bulbar con-
junctival redness and watery conjunctival discharge scores; 
total score 0–6). Crossover infection to a fellow eye was also 
recorded, based on the presence (scores .0) of both watery 
conjunctival discharge and bulbar conjunctival redness (only 
patients with one eye that did not show both signs of viral 
conjunctivitis at baseline were included).
All patients had a Rapid Pathogen Screening (RPS) 
Adeno-Detector Plus™ test (Rapid Pathogen Screening Inc., 
Sarasota, FL, USA) performed at the Day 1 visit on both 
eyes to identify, in office, whether they were RPS positive or 
negative. RPS-positive testing was not an inclusion criterion 
for the study. Conjunctival swabs of both eyes were taken 
at each visit using a flocked swab kit (Copan Diagnostics, 
Murrieta, CA, USA) and frozen at -70°C until analysis. 
Adenovirus testing with cell culture immunofluorescence 
assay (CC-IFA) and quantitative PCR ($100 copies/mL 
was positive) was conducted on samples from eyes that were 
RPS positive at Visit 1.
safety assessments
Adverse events (AEs; reported, elicited, and observed), 
slit-lamp biomicroscopy, and BSCVA were documented 
at all study visits. The definition of AEs included any pre-
existing medical condition that worsened after administration 
of the study drug, for example, the significant worsening 
of viral conjunctivitis. Treatment-emergent AEs (TEAEs) 
were defined as events that occurred or worsened after the 
first dose. BSCVA was assessed using an Early Treatment 
Diabetic Retinopathy Study chart. Urine pregnancy test and 
nondilated fundus exam were performed at all visits except 
the Day 3 visit.
statistical analyses
The primary population for the efficacy analysis was based 
on the modified intention-to-treat (mITT) population, con-
sisting of patients in the intention-to-treat (ITT) population 
(randomized patients who received at least one dose of 
study medication) who had at least one visit after the Day 1 
visit, and had a score $1 for watery conjunctival discharge 
and bulbar conjunctival redness scores in the same eye at 
the Day 1 visit. An additional analysis population was the 
viral-positive population, consisting of patients in the mITT 
population with a positive adenoviral test at the Day 1 visit 
in either eye by any method (RPS, CC-IFA, and/or quantita-
tive PCR). The safety population consisted of randomized 
patients who received at least one dose of study medication.
A chi-square or Fisher’s exact test (for expected 
count ,5) was used to compare treatment groups with 
respect to binary endpoints, and a 2-sample t-test was used 
to compare groups with respect to continuous endpoints. 
Testing was conducted at a two-sided 0.05 significance level.
Viral titer was assessed by quantitative PCR at each 
follow-up visit and summarized in the study eye by treatment 
group. The proportions of patients with a 3-point reduction 
from baseline in viral titer (log 10 transformed scale) in the 
two study arms were compared using a chi-squared test. If the 
viral test was negative (ie, ,100 copies/mL), then the viral 
titer was considered to be 0. Due to the nature of the titer data, 
log base 10 transformations were performed on the raw data 
before any analyses were performed. To account for a value 
of 0 (ie, when the titer results are “negative”), 0.5 was added 
to all values before the log 10 transformations were taken.
The study eye was preliminarily designated by the 
investigator at the time of enrollment (baseline), based on 
signs alone. If both eyes had signs of viral conjunctivitis 
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on whichever eye had the greater cumulative score for watery 
conjunctival discharge and bulbar conjunctival redness at 
baseline. If both eyes had the same cumulative score, then 
the baseline-designated study eye was the right eye. For the 
analysis, in patients with only one eye with a positive adenovi-
ral test by PCR and score $1 for watery conjunctival discharge 
and bulbar conjunctival redness at baseline, the infected eye 
was the study eye. If both eyes at baseline were positive for 
adenoviral testing and had sign scores of $1, the eye with the 
greater cumulative score for conjunctival discharge and redness 
at baseline was the study eye. If both eyes had the same cumu-
lative score, then the study eye was the right eye. For patients 
with neither eye with a positive adenoviral test at baseline, the 
baseline-designated study eye was defined as the study eye.
Because this was a Phase II study, formal sample size 
calculations were not performed, but a sample size of 120 
evaluable patients (60 per treatment arm) was deemed reason-




The study was conducted between May 2013 and March 2014. 
A total of 132 patients were randomized and 99 completed the 
study (Figure 2). The safety and ITT populations contained 
all 132 patients, while the mITT population contained 
115 patients. A total of 38 patients (PVP-I/DEX, n=18; vehicle, 
n=20) continued into the open-label portion of the study.
The mean (SD) age across all patients in the ITT popula-
tion was 31.0 (9.87) years. Most patients were female (62.9%) 
and nearly all (97.0%) were of Hispanic or Latino ethnicity 
(Table 1). Four patients in the vehicle group and five in the 
PVP-I/DEX group were recorded as noncompliant with dos-
ing. Altogether, 131 (99.2%) patients had a primary clinical 
diagnosis of viral conjunctivitis. With the exception of the 
primary diagnosis, the most common (.5%) occurrences 
in ocular medical history for all patients were eyelid edema 
(22.0%), optic nerve disorders (12.1%), keratitis (9.8%), 
corneal infiltrates (6.8%), and pinguecula (5.3%). The most 
common nonocular medical history included hypertension 
(5.3%), postmenopause (4.5%), female sterilization (3.0%), 
rhinitis (2.3%), gastritis (2.3%), and diabetes mellitus (2.3%).
Viral status
Confirmatory adenovirus testing was planned to be carried 
out on baseline RPS-positive eyes at each visit using CC-IFA 
and quantitative PCR. At baseline, adenovirus testing was 
conducted on 27 and 23 mITT patients in the PVP-I/DEX 
and vehicle groups, respectively. Of these, adenovirus was 
detected by CC-IFA and/or quantitative PCR in either eye of 
59.3% (16/27) and 69.6% (16/23) of patients in the PVP-I/
DEX and vehicle groups, respectively. At the Day 3 visit, 
73.7% (14/19) and 77.8% (14/18) of patients in those groups 
were adenovirus positive. At the Day 6 visit, 70.6% (12/17) 
and 77.8% (14/18) of patients were adenovirus positive. 
At the Day 11–14 visit, 50.0% (6/12) and 45.5% (5/11) of 
patients were adenovirus positive, respectively. The two 
treatment groups were not statistically different from each 
other in viral status at any visit.
Figure 2 Patient disposition.
Notes: The viral-positive population consisted of all patients in the modified ITT 
population with a positive viral test at Visit 1 in either eye by any method (rapid 
Pathogen Screening, cell culture immunofluorescence assay, and/or quantitative 
polymerase chain reaction).






























age, y, mean (sD) 30.2 (9.34) 31.8 (10.39) 31.0 (9.87)
sex, n (%)    
Male 20 (30.3) 29 (43.9) 49 (37.1)
Female 46 (69.7) 37 (56.1) 83 (62.9)
ethnicity, n (%)    
hispanic or latino 64 (97.0) 64 (97.0) 128 (97.0)
race, n (%)    
asian 0 1 (1.5) 1 (0.8)
Black or african 
american
27 (40.9) 21 (31.8) 48 (36.4)
White 38 (57.6) 44 (66.7) 82 (62.1)
Other 1 (1.5) 0 1 (0.8)
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The agreement between the adenovirus tests was as 
follows: 65.45% (36/55) of eyes tested for both RPS and 
CC-IFA at baseline had consistent results between the two 
tests. The agreement between the RPS and quantitative PCR 
tests was 73.85% [48/65] of eyes tested at baseline; and 
between the CC-IFA and quantitative PCR tests, the agree-
ment was 72.68% [133/183] of eyes tested across all visits.
Efficacy
Clinical resolution
Analysis in the mITT population with last observation carried 
forward (LOCF) showed no statistical difference between the 
PVP-I/DEX and vehicle groups at the Day 6 visit for clinical 
resolution (66.1% [39/59] PVP-I/DEX vs 58.9% [33/56] 
vehicle; P=0.4268). The proportions of patients with resolu-
tion of individual conjunctival signs in the study eye at the 
Day 6 visit were numerically higher in the PVP-I/DEX group 
compared with the vehicle group, but the difference was not 
statistically significant (watery conjunctival discharge, 76.3% 
[45/59] PVP-I/DEX vs 62.5% [35/56] vehicle; P=0.1087; 
bulbar conjunctival redness, 67.8% [40/59] PVP-I/DEX vs 
60.7% [34/56] vehicle; P=0.4280). Less than one-quarter 
(24.2%; 32/132) of patients had confirmed adenoviral con-
junctivitis in either eye at baseline, but an attempt was made 
to analyze the data in these patients. At the Day 6 visit, in 
the viral-positive population with LOCF, there were no sta-
tistically significant differences between treatment groups in 
clinical resolution (33.3% [7/21] PVP-I/DEX vs 28.6% [6/21] 
vehicle; P=0.7385), or in resolution of watery conjunctival 
discharge (42.9% [9/21] PVP-I/DEX vs 33.3% [7/21] vehicle; 
P=0.5251), or resolution of bulbar conjunctival redness (33% 
[7/21] PVP-I/DEX vs 33.3% [7/21] vehicle; P=0.9999).
In the extension phase of the study (during which all 
patients received open-label PVP-I/DEX after the Day 6 
visit), 60.0% (9/15) of patients in the ITT population who 
had received PVP-I/DEX before the Day 6 visit achieved 
clinical resolution compared with 44.4% (8/18) who were in 
the vehicle-treated group before the Day 6 visit; the between-
group difference was not statistically significant (P=0.3733). 
As with the masked part of the study, there were few patients 
in the extension with confirmed adenoviral conjunctivitis, but 
an attempt was made to analyze these data. In this limited 
population, a positive adenoviral test did not appear to have 
an impact on the response rate (54.5% [6/11] PVP-I/DEX 
vs 50.0% [5/10] vehicle; P=0.8350).
Other efficacy endpoints
Viral titers were similar between the two treatment groups at 
all visits in the viral-positive population. In this population, 
at the Day 6 visit, 12.5% (2/16) of patients in the PVP-I/DEX 
group achieved a 3-point reduction (log 10 transformed scale) 
from baseline in viral titer in the study eye compared with 
17.6% (3/17) of patients in the vehicle-treated group; the 
difference was not statistically significant (P=0.9999). In the 
mITT population, there were no reductions in viral conjunc-
tivitis (study and fellow eyes) between the PVP-I/DEX and 
vehicle treatment groups at any visit as measured by adeno-































Positive quantitative PCR results (study eye)
Open-label
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Positive CC-IFA results (study eye)
Open-label
extension
Day 3+1 Day 6+1 Days 11–14
PVP-I/DEX Vehicle
Figure 3 Adenovirus detection in the modified ITT population.
Notes: There were no significant differences in detected adenovirus between treatment groups at all visits. Positive is defined as $100 copies/ml for quantitative PCr and 
“detected” virus for CC-iFa. Percentages are based on the number of eyes in each group with reported results. Values inside bars = number of eyes with positive result/total 
number of eyes in each group with reported results.
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Table 3 Change from baseline in global clinical score at Day 6 (+1-day window; study eye)
 ITT population with positive 
adenoviral test
mITT population with LOCF
PVP-I/DEX n=21 Vehicle n=21 PVP-I/DEX n=59 Vehicle n=56
n 19 20 59 56
Mean (sD) score -2.3 (1.60) -1.4 (2.58) -3.1 (1.44) -2.5 (2.22)
P-value vs vehicle 0.1904 0.1207
Patients with a 3-point reduction from baseline, n (%) 11 (57.9) 6 (30.0) 45 (76.3) 29 (51.8)
P-value vs vehicle 0.0791 0.0061
Patients with a reduction of $50% from baseline, n (%) 14 (73.7) 8 (40.0) 52 (88.1) 38 (67.9)
P-value vs vehicle 0.0340 0.0084
Patients with any improvement from baseline, n (%) 16 (84.2) 13 (65.0) 55 (93.2) 46 (82.1)
P-value vs vehicle 0.2733 0.0895
Notes: The global clinical score is the sum of watery conjunctival discharge and bulbar conjunctival redness, both assessed on integer scales of 0–3. higher scores are 
indicative of greater severity. n in the header is the total number of patients enrolled in each treatment group; n in the table is the number of patients with nonmissing data 
and is used for calculating percentages where appropriate.
Abbreviations: DEX, dexamethasone; ITT, intention-to-treat; LOCF, last observation carried forward; mITT, modified intention-to-treat; PVP-I, povidone-iodine.
Table 2 Crossover infection to the fellow eye (miTT population)
Crossover infection PVP-I/DEX n=59 Vehicle n=56
any follow-up visit n=20 n=17
n (%) 2 (10.0) 4 (23.5)
Day 3 visit n=18 n=17
n (%) 2 (11.1) 4 (23.5)
Day 6 visit n=19 n=16
n (%) 0 1 (6.3)
Day 11–14 visit n=1 n=3
n (%) 0 0
Notes: Crossover infection is defined as the presence (scores .0) of both watery 
conjunctival discharge and bulbar conjunctival redness. Only patients with one eye 
that did not show both signs of viral conjunctivitis at baseline are included. n in the 
header is the total number of patients enrolled in each treatment group within 
the miTT population; n in the table is the number of patients with nonmissing data 
and is used for calculating the percentages.
Abbreviations: DEX, dexamethasone; mITT, modified intention-to-treat; PVP-I, 
povidone-iodine.
In the mITT population with LOCF, the percentage of 
patients who met the definition of expanded clinical cure in 
the study eye at the Day 6 visit was numerically higher in the 
PVP-I/DEX group (76.3%; 45/59) compared with the vehicle 
group (62.5%; 35/56); the difference was not statistically 
significant (P=0.1087).
The proportion of patients with crossover infec-
tion, defined as the presence (scores .0) of both watery 
conjunctival discharge and bulbar conjunctival redness, was 
lower in the PVP-I/DEX group compared with the vehicle 
group (Table 2).
In patients with a positive adenoviral test among the ITT 
population, at the Day 3 visit, a reduction from baseline in 
global clinical score (mean change, -1.5 vs 0.1; P=0.0078) 
or the proportion of patients with any improvement from 
baseline in global clinical score (75.0% [15/20] PVP-I/DEX 
vs 30.0% [6/20] vehicle; P=0.0044) were significantly greater 
with PVP-I/DEX compared with vehicle. Between-group 
differences for the proportions of patients with a 3-point 
reduction (25% [5/20] PVP-I/DEX vs 10% [2/20] vehicle) 
or $50% reduction (40% [8/20] PVP-I/DEX vs 15% [3/20] 
vehicle) from baseline in global clinical score were not 
statistically significant at this time point. At the Day 6 visit 
in this population, of the various measures of change from 
baseline in global clinical score shown in Table 3, only 
the proportion of patients in the PVP-I/DEX group with a 
reduction of $50% from baseline was significantly greater 
compared with the vehicle group (Table 3).
In the mITT population with LOCF, at the Day 6 visit, a 
reduction from baseline in global clinical score or the propor-
tion of patients with any improvement from baseline in global 
clinical score were numerically greater with PVP-I/DEX vs 
vehicle, although the differences were not significantly differ-
ent (Table 3). Between-group differences for the proportion 
of patients with a 3-point or $50% reduction from baseline 
in global clinical score significantly favored PVP-I/DEX at 
this time point (Table 3).
safety
There were no serious AEs or deaths during the course of this 
study and no patients discontinued as a result of an AE. In 
addition, no patterns of AEs that suggested systemic toxici-
ties or localized complications were identified. In the masked 
phase of this study, of patients receiving PVP-I/DEX, 51.5% 
(34/66) reported at least one ocular TEAE compared with 
39.4% (26/66) in the vehicle group; 78.9% (30/38) of patients 
in the open-label phase experienced at least one ocular TEAE. 
Considerably fewer patients reported at least one nonocular 
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(8/66) vehicle; open-label phase, 10.5% (4/38)]. The most 
frequently reported ocular (.5% of patients) or nonocular 
(.1 patient) TEAEs in either treatment group are presented 
in Table 4. In the masked phase, all ocular and nonocular 
TEAEs in the PVP-I/DEX group were considered to be mild 
in severity. In the open-label extension, two ocular TEAEs 
(reduced visual acuity and scarring) reported by 2.6% (1/38) 
of patients receiving PVP-I/DEX were classified as moder-
ate; all other TEAEs in the extension were considered to be 
mild (Table 4).
In the masked phase, 34.8% (23/66) of patients in the 
PVP-I/DEX group reported a total of 23 ocular TEAEs in 
the study eye that were suspected to be related to the study 
treatment. These were predominantly mild instillation-site 
pain (21/23 ocular TEAEs). The most frequently reported 
ocular TEAEs that were not suspected of being related to 
study treatment in the PVP-I/DEX group included corneal 
infiltrates (reported by 3.0% and 4.5% of patients in the study 
eye and fellow eye, respectively), ocular pruritus (reported by 
3.0% of patients in both the study eye and fellow eye), and 
viral conjunctivitis (reported by 4.5% and 1.5% of patients 
in the study eye and fellow eye, respectively). No nonocular 
TEAEs were suspected to be related to treatment in the PVP-I/
DEX treatment group during the masked phase of the study.
In the open-label phase, ocular TEAEs (mild corneal 
infiltrates, mild keratitis, and mild instillation-site pain) 
were reported in 78.9% (30/38) of patients. Four nonocular 
TEAEs were reported in 10.5% (4/38) of the open-label–
treated patients. These were pyrexia, dizziness, headache, 
and dysmenorrhea. Only the dizziness (mild in severity) 
was suspected of being related to study treatment (Table 4).
In the masked and open-label phases of the study, the only 
nonocular TEAEs that were reported in more than one patient 
in any treatment group were headache and dizziness (Table 4).
Slit-lamp biomicroscopy examinations revealed several 
cases of shifts from normal at baseline to abnormal (clinically 
significant or nonclinically significant) at subsequent visits. 
These shifts were noted across treatment groups and visits 
predominantly for evaluations of the cornea. There were no 
clinically significant abnormal findings with fundoscopic 
examinations of the optic nerve after treatment with PVP-I/
DEX or vehicle. Mean changes in BSCVA over the course of 
the study did not show any notable increases in score in any 
treatment group; however, there were some individuals who 
experienced a change in BSCVA of $0.22 logMAR (Day 3 
visit, 0 PVP-I/DEX vs 7.4% [4/54] vehicle; Day 6 visit, 3.6% 
[2/55] PVP-I/DEX vs 3.7% [2/54] vehicle; Day 11–14 visit, 
5.0% [1/20] PVP-I/DEX vs 10.0% [2/20] vehicle).
Discussion
The present study intended to evaluate the superiority of 
PVP-I/DEX ophthalmic suspension compared with vehicle 
Table 4 summary of most frequent treatment-emergent adverse events (safety population)
 Masked phase Open-label phase
PVP-I/DEX (n=66), n (%) Vehicle (n=66), n (%) PVP-I/DEX (n=38), n (%)
Study eyea Fellow eyea Study eyea Fellow eyea Study eyea Fellow eyea
Patients with $1 Teae 37 (56.1) 29 (43.9) 30 (78.9)
Ocular Teaes 34 (51.5) 26 (39.4) 30 (78.9)
Mild 32 (48.5) 28 (42.4) 18 (27.3) 15 (22.7) 27 (71.1) 24 (63.2)
Moderate 0 0 1 (1.5) 0 1 (2.6) 0
severe 0 0 0 0 0 0
nonocular Teaes 3 (4.5) 8 (12.1) 4 (10.5)
Mild 3 (4.5) 8 (12.1) 4 (10.5)
Moderate 0 0 0
severe 0 0 0
Most frequent (.5%) ocular Teaes
Corneal infiltrates 2 (3.0) 3 (4.5) 6 (9.1) 3 (4.5) 20 (52.6) 14 (36.8)
eyelid edema 2 (3.0) 2 (3.0) 4 (6.1) 1 (1.5) 3 (7.9) 3 (7.9)
Keratitis 3 (4.5) 0 6 (9.1) 4 (6.1) 8 (21.1) 6 (15.8)
instillation-site pain 21 (31.8) 21 (31.8) 2 (3.0) 2 (3.0) 6 (15.8) 6 (15.8)
Conjunctivitis viral 3 (4.5) 1 (1.5) 1 (1.5) 7 (10.6) 1 (2.6) 7 (18.4)
Most frequent (n.1) nonocular Teaes
headache 2 (3.0) 4 (6.1) 1 (2.6)
Dizziness 0 2 (3.0) 1 (2.6)
Notes: Percentages are based on the total number of patients in each treatment group. aWhere applicable.
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for clinical resolution of acute viral conjunctivitis, but not 
enough patients with confirmed adenoviral conjunctivitis 
were enrolled to assess the primary efficacy endpoint for 
PVP-I/DEX. An attempt was made to analyze the data on 
patients with confirmed adenoviral conjunctivitis; however, 
there was very little remaining statistical power to assess 
efficacy. Overall, some trends toward efficacy were observed 
for PVP-I/DEX, and the drug combination had a favorable 
safety profile and was generally well tolerated in this study, 
with no serious ocular TEAEs reported and no patients 
withdrawn from the study due to an AE.
Less than one-quarter (n=32/132) of patients in this 
study had confirmed adenoviral conjunctivitis at baseline 
by CC-IFA or quantitative PCR. A positive RPS Adeno-
Detector Plus test was not an inclusion criterion in this study, 
which could explain the low number of adenoviral-positive 
patients enrolled, because an accurate diagnosis of viral con-
junctivitis based on clinical signs is known to be difficult.18 
In contrast, in a Phase II efficacy and safety trial conducted 
in India that included only RPS-positive patients, sufficient 
numbers of patients with confirmed adenoviral conjunctivitis 
were enrolled (81.8% of randomized patients) and PVP-I/
DEX demonstrated statistical superiority to vehicle for clini-
cal resolution, adenoviral eradication, global clinical score, 
and expanded clinical cure.17 In the present study, although 
we were not able to assess the primary efficacy endpoint, 
some improvements in global clinical scores were observed 
following treatment with PVP-I/DEX in patients with a 
positive adenoviral test among the ITT population and in the 
mITT population with LOCF. PVP-I/DEX also appeared to 
have a benefit relative to crossover infection rates, with lower 
proportions of patients with crossover infection compared 
with vehicle treatment.
The observed safety profile of PVP-I/DEX in this study 
appeared to be consistent with the well-characterized safety 
profiles of PVP-I and DEX, and no patterns of AEs indica-
tive of systemic toxicities or localized complications were 
identified. Overall, no serious AEs were reported and the 
majority of TEAEs were ocular in nature and mild in severity. 
Most of the AEs with a suspected relationship to treatment 
with PVP-I/DEX consisted of mild instillation-site pain. All 
nonocular TEAEs were mild and the only nonocular TEAEs 
that occurred in more than one patient in any treatment group 
were headache and dizziness. Importantly, no patients in this 
study discontinued due to AEs. The safety and tolerability 
results of the present study are consistent with results from 
the study conducted in India.17 In both studies, there were 
no increases in AEs that have been previously associated 
with the use of topical ocular corticosteroids, ie, increases in 
intraocular pressure, cataract development, or glaucoma.19–21
Infectious conjunctivitis is a clinically challenging condi-
tion due to the overlap of symptoms between bacterial and 
viral causes and because no treatment is approved for viral 
conjunctivitis. A drug that treats both adenoviral and bacterial 
conjunctivitis would mitigate the negative effects of misdi-
agnosis, which can occur in up to 50% of cases.22 Phase III 
clinical trials are ongoing in adults and children to evaluate 
the efficacy and safety of PVP-I 0.6%/DEX 0.1% in adeno-
viral conjunctivitis (NCT02998541 and NCT02998554).
Potential limitations of this study are that the study was 
conducted in a single country and that serotyping was not 
performed, which may limit the generalizability of the results. 
In addition, according to the instructions of the RPS Adeno-
Detector Plus test used, the sensitivity of the test was 84%, 
so negative test samples that were not subsequently tested 
by quantitative PCR or CC-IFA could have been positive for 
adenovirus or other viruses.
Future studies evaluating the efficacy of PVP-I/DEX 
could be improved by modifying study eligibility criteria to 
increase the likelihood of enrolling subjects with confirmed 
adenoviral conjunctivitis. This may be achieved by the use of 
the AdenoPlus® test as a screening test and/or better clinical 
assessment criteria. A study with an adequate number of 
subjects with adenoviral conjunctivitis confirmed by culture 
would enable a robust assessment of efficacy.
Conclusion
The QID dosing of PVP-I 0.6%/DEX 0.1% ophthalmic sus-
pension for #14 days was generally well tolerated, with no 
unexpected TEAEs, and a safety profile that was consistent 
with the known pharmacological profile of PVP-I and DEX. 
Overall, some trends toward efficacy were observed for 
PVP-I/DEX, but large Phase III trials enrolling a high pro-
portion of patients with confirmed adenoviral conjunctivitis 
are needed to further evaluate the efficacy of this product 
for adenoviral conjunctivitis. Such studies are ongoing and 
should provide important information.
Ethics approval and informed 
consent
This trial was compliant with the principles of the Declaration 
of Helsinki and the International Conference on Harmoniza-
tion guidelines for Good Clinical Practice; it was registered 
at ClinicalTrials.gov (identifier, NCT01461954). Written 
informed consent was obtained from each patient prior to 
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reviewed and approved by Alpha Independent Review Board 
(San Clemente, CA, USA) and Comitê de Ética em Pesquisa 
da Universidade Federal de São Paulo (São Paulo, Brazil).
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